Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
0.7099
-0.0166 (-2.28%)
Sep 17, 2025, 4:00 PM EDT - Market closed
Silo Pharma Revenue
Silo Pharma had revenue of $18.03K in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $72.10K. In the year 2024, Silo Pharma had annual revenue of $72.10K.
Revenue (ttm)
$72.10K
Revenue Growth
n/a
P/S Ratio
49.32
Revenue / Employee
$24,034
Employees
3
Market Cap
6.72M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 72.10K | - | - |
Dec 31, 2023 | 72.10K | - | - |
Dec 31, 2022 | 72.10K | 838.00 | 1.18% |
Dec 31, 2021 | 71.26K | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
SILO News
- 1 day ago - Silo Pharma Announces Initial Investment in Ethereum and Solana under Cryptocurrency Treasury Strategy - GlobeNewsWire
- 8 days ago - Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug - GlobeNewsWire
- 14 days ago - Silo Pharma Secures Australian Patent Covering Licensed PTSD Drug Candidate Expanding Global IP Portfolio - GlobeNewsWire
- 27 days ago - Silo Pharma's Alzheimer's Candidate SPC-14 Featured in Leading Scientific Peer-reviewed Journal - GlobeNewsWire
- 4 weeks ago - Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway - GlobeNewsWire
- 6 weeks ago - Silo Pharma Appoints Crypto Infrastructure Pioneer Corwin Yu to Launch Institutional Bitcoin, Ethereum and Solana Treasury Platform - GlobeNewsWire
- 2 months ago - Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15 - GlobeNewsWire
- 2 months ago - Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025 - GlobeNewsWire